{"id":2400,"date":"2023-02-10T15:16:22","date_gmt":"2023-02-10T14:16:22","guid":{"rendered":"https:\/\/jjpbiologics.com\/?p=2400"},"modified":"2023-03-03T17:02:01","modified_gmt":"2023-03-03T16:02:01","slug":"zapytanie-z-dnia-10-02-2023-2","status":"publish","type":"post","link":"https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/","title":{"rendered":"Zapytanie z dnia 10\/02\/2023"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"2400\" class=\"elementor elementor-2400\" data-elementor-settings=\"[]\">\n\t\t\t\t\t\t<div class=\"elementor-inner\">\n\t\t\t\t\t\t\t<div class=\"elementor-section-wrap\">\n\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a6c4773 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a6c4773\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t\t\t<div class=\"elementor-row\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4540d693 sc_inner_width_none sc_layouts_column_icons_position_left\" data-id=\"4540d693\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-column-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-546d1720 elementor-widget elementor-widget-text-editor\" data-id=\"546d1720\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-text-editor elementor-clearfix\"><p><span style=\"font-size: 16px;\">RFP2302_T01_JJA_01 Legal services<\/span><\/p><ul><li><span style=\"font-size: 16px;\">W zwi\u0105zku z realizacj\u0105 projektu rozwoju kandydata na lek o tytule \u201eDevelopment of first-in-class antibody therapy for treatment of the ultra-rare LABD indication as well as for pulmonary and autoimmune diseases with IgA mediated pathology, using Companion Diagnostics (CDx) patient stratification for treatment with the JJP-1212&#8243; w ramach konkursu Rozw\u00f3j medycyny celowanej lub personalizowanej na bazie terapii kom\u00f3rkowych lub produkt\u00f3w bia\u0142kowych, organizowanego przez Agencj\u0119 Bada\u0144 Medycznych, og\u0142aszamy zapytanie ofertowe na realizacj\u0119\u00a0<\/span><b style=\"font-size: 16px;\">us\u0142ugi\u00a0<\/b><span style=\"color: #121619;\"><span style=\"font-size: 16px;\"><b>przegl\u0105du prawnego umowy z CRO dotycz\u0105cej przeprowadzenia badania klinicznego fazy 1 oraz udzia\u0142 w negocjacjach<\/b><\/span><\/span><b style=\"font-size: 16px;\">\u00a0<\/b><b style=\"color: #121619; font-size: 16px;\">(ang.\u00a0<\/b><span style=\"color: #121619;\"><span style=\"font-size: 16px;\"><b>legal review of the agreement with the CRO regarding conducting of Phase 1 clinical study and participation in negotiations<\/b><\/span><\/span><b style=\"color: #121619; font-size: 16px;\">)<\/b><span style=\"font-size: 16px;\">.<\/span><\/li><li style=\"font-size: 16px;\">Szczeg\u00f3\u0142y zapytania zostan\u0105 przekazane ka\u017cdorazowo po podpisaniu umowy o zachowaniu poufno\u015bci, w terminie 2 dni, lub po zg\u0142oszeniu si\u0119 podmiotu z\u00a0aktywn\u0105 umow\u0105 o zachowaniu poufno\u015bci. Wz\u00f3r umowy do pobrania\u00a0<a style=\"font-size: 16px; background-color: #ffffff;\" href=\"http:\/\/jjpbiologics.com\/wp-content\/uploads\/2023\/03\/2023_01_20_bi-lingual-NDA-JJPBio.docx\">LINK<\/a><span style=\"font-size: 16px;\">.<\/span><\/li><li><span style=\"font-size: 16px;\">Termin na sk\u0142adnie ofert: 24.02.2023.<\/span><\/li><li style=\"font-size: 16px;\"><span style=\"font-family: Hind, sans-serif; font-size: 16px; font-style: normal; font-weight: 400;\">Pytania i kontakt w zwi\u0105zku z zapytaniem prosz\u0119 kierowa\u0107 na adres:\u00a0<\/span><img decoding=\"async\" src=\"data:image\/png;base64,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\" alt=\"\" \/><img decoding=\"async\" src=\"data:image\/png;base64,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\" alt=\"\" \/><img decoding=\"async\" style=\"margin-bottom: 0px;\" src=\"data:image\/png;base64,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\" alt=\"\" \/><\/li><\/ul><div><div style=\"margin-left: -15px; margin-right: -15px;\" data-elementor-type=\"wp-post\" data-elementor-id=\"2396\" data-elementor-settings=\"[]\"><section data-id=\"a6c4773\" data-element_type=\"section\"><div style=\"max-width: 1260px;\"><div style=\"width: 1260px;\"><div style=\"width: 1260px;\" data-id=\"4540d693\" data-element_type=\"column\"><div style=\"width: 1260px;\"><div style=\"width: 1230px;\"><div style=\"width: 1230px;\" data-id=\"546d1720\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\"><p style=\"font-family: Hind, sans-serif; font-size: 17px; font-style: normal; font-weight: 400; margin-bottom: 1.8em;\">Otrzymane pytania dotycz\u0105ce specyfikacji zam\u00f3wienia:<\/p><ol><li style=\"list-style-type: none;\"><ol><li><span style=\"font-size: 17px;\">W odniesieniu do \u017c\u0105danych referencji &#8211; jakiego rodzaju informacje spe\u0142ni\u0105 wymagania JJP Biologics? Czy mam rozumie\u0107, \u017ce powinienem uzyska\u0107 list (lub email) od zdecydowanego klienta potwierdzaj\u0105cy wykonanie okre\u015blonej pracy? Czy wiadomo\u015b\u0107 e-mail by\u0142aby wystarczaj\u0105ca? Czy wymagane by\u0142oby uzyskanie potwierdzenia na temat dok\u0142adnej liczby um\u00f3w, kt\u00f3re przegl\u0105dali\u015bmy? Obawiamy si\u0119, \u017ce klient mo\u017ce nie pami\u0119ta\u0107 dok\u0142adnie, lub uzyskanie dok\u0142adnych informacji mo\u017ce by\u0107 trudne, zw\u0142aszcza w przypadku instrukcji wykonanych jaki\u015b czas temu, lub je\u015bli klientowi zale\u017cy na poufno\u015bci.<br \/><\/span><b style=\"font-size: 17px;\">Odpowied\u017a:<\/b><span style=\"font-size: 17px;\"><span style=\"font-size: 17px;\">\u00a0Email od Cz\u0142onka Zarz\u0105du lub co najmniej osoby odpowiedzialnej za projekt na stronie klienta b\u0119dzie wystarczaj\u0105cy (email powinien zawiera\u0107 nazw\u0119 kancelarii zaanga\u017cowanej w projekt, typ umowy przygotowanej i negocjowanej przez kancelari\u0119 oraz dat\u0105 pracy nad umow\u0105).<\/span><\/span><p>\u00a0<\/p><\/li><li><span style=\"font-size: 16px; color: #121619;\"><span style=\"font-size: 17px;\">Czy dobrze rozumiem, \u017ce limit powinien obejmowa\u0107 nie tylko przewidywane 60 h pracy, ale r\u00f3wnie\u017c wszelkie dodatkowe godziny pracy, w przypadku gdyby by\u0142y one potrzebne do zamkni\u0119cia projektu?<\/span><\/span><br \/><b style=\"font-family: inherit; font-size: 15px; font-style: inherit;\">Odpowied\u017a<\/b><span style=\"font-family: Hind, sans-serif; font-style: normal; font-weight: 400; font-size: 17px; color: #121619;\">:\u00a0<\/span><span style=\"font-size: 16px; color: #121619;\"><span style=\"font-size: 17px;\">Prosimy o podanie stawki godzinowej, gdy\u017c jak opisujemy w RFP, chcemy by\u0107 rozliczani za prace prawne na podstawie ilo\u015bci przepracowanych godzin. Niemniej, chcemy ustali\u0107 limit na prac\u0119 nad pierwsz\u0105 wersj\u0105 umowy oraz w ramach dw\u00f3ch rund negocjacyjnych (kt\u00f3re oszacowali\u015bmy na max 60 godzin). Wszelkie dodatkowe negocjacje po drugiej rundzie mog\u0105 by\u0107 rozliczane powy\u017cej limitu.\u00a0<\/span><\/span><\/li><\/ol><\/li><\/ol><p style=\"font-size: 15px;\">\u00a0<\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/div><div style=\"font-size: 17px; line-height: 1.3em; text-transform: none; letter-spacing: normal; margin-bottom: 2em; margin-top: 2.8em; overflow: hidden; clear: both;\">\u00a0<\/div><\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>RFP2302_T01_JJA_01 Legal services W zwi\u0105zku z realizacj\u0105 projektu rozwoju kandydata na lek o tytule \u201eDevelopment of first-in-class antibody therapy for&hellip;<\/p>","protected":false},"author":990005,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"elementor_theme","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[64],"tags":[62],"class_list":["post-2400","post","type-post","status-publish","format-standard","hentry","category-zapytania","tag-jjp1212"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Zapytanie z dnia 10\/02\/2023 - JJP Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zapytanie z dnia 10\/02\/2023 - JJP Biologics\" \/>\n<meta property=\"og:description\" content=\"RFP2302_T01_JJA_01 Legal services W zwi\u0105zku z realizacj\u0105 projektu rozwoju kandydata na lek o tytule \u201eDevelopment of first-in-class antibody therapy for&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/\" \/>\n<meta property=\"og:site_name\" content=\"JJP Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-10T14:16:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-03T16:02:01+00:00\" \/>\n<meta name=\"author\" content=\"jjp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"jjp\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/\"},\"author\":{\"name\":\"jjp\",\"@id\":\"https:\/\/jjpbiologics.com\/#\/schema\/person\/85e5b4f7346f1b3e0e153562849f7a43\"},\"headline\":\"Zapytanie z dnia 10\/02\/2023\",\"datePublished\":\"2023-02-10T14:16:22+00:00\",\"dateModified\":\"2023-03-03T16:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/\"},\"wordCount\":408,\"publisher\":{\"@id\":\"https:\/\/jjpbiologics.com\/#organization\"},\"keywords\":[\"JJP1212\"],\"articleSection\":[\"Zapytania\"],\"inLanguage\":\"pl-PL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/\",\"url\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/\",\"name\":\"Zapytanie z dnia 10\/02\/2023 - JJP Biologics\",\"isPartOf\":{\"@id\":\"https:\/\/jjpbiologics.com\/#website\"},\"datePublished\":\"2023-02-10T14:16:22+00:00\",\"dateModified\":\"2023-03-03T16:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jjpbiologics.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zapytanie z dnia 10\/02\/2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jjpbiologics.com\/#website\",\"url\":\"https:\/\/jjpbiologics.com\/\",\"name\":\"JJP Biologics\",\"description\":\"Innovative and revolutionary biologics\",\"publisher\":{\"@id\":\"https:\/\/jjpbiologics.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jjpbiologics.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/jjpbiologics.com\/#organization\",\"name\":\"JJP Biologics\",\"url\":\"https:\/\/jjpbiologics.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/jjpbiologics.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/jjpbiologics.com\/wp-content\/uploads\/2021\/06\/cropped-Artboard-31.png\",\"contentUrl\":\"https:\/\/jjpbiologics.com\/wp-content\/uploads\/2021\/06\/cropped-Artboard-31.png\",\"width\":1000,\"height\":567,\"caption\":\"JJP Biologics\"},\"image\":{\"@id\":\"https:\/\/jjpbiologics.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/jjpbiologics.com\/#\/schema\/person\/85e5b4f7346f1b3e0e153562849f7a43\",\"name\":\"jjp\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/jjpbiologics.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7af8c453e36d80c5694e711800454903b7530678990eb7442d82d1b8c1f95609?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7af8c453e36d80c5694e711800454903b7530678990eb7442d82d1b8c1f95609?s=96&d=mm&r=g\",\"caption\":\"jjp\"},\"url\":\"https:\/\/jjpbiologics.com\/pl\/author\/jjp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zapytanie z dnia 10\/02\/2023 - JJP Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/","og_locale":"pl_PL","og_type":"article","og_title":"Zapytanie z dnia 10\/02\/2023 - JJP Biologics","og_description":"RFP2302_T01_JJA_01 Legal services W zwi\u0105zku z realizacj\u0105 projektu rozwoju kandydata na lek o tytule \u201eDevelopment of first-in-class antibody therapy for&hellip;","og_url":"https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/","og_site_name":"JJP Biologics","article_published_time":"2023-02-10T14:16:22+00:00","article_modified_time":"2023-03-03T16:02:01+00:00","author":"jjp","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"jjp","Szacowany czas czytania":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#article","isPartOf":{"@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/"},"author":{"name":"jjp","@id":"https:\/\/jjpbiologics.com\/#\/schema\/person\/85e5b4f7346f1b3e0e153562849f7a43"},"headline":"Zapytanie z dnia 10\/02\/2023","datePublished":"2023-02-10T14:16:22+00:00","dateModified":"2023-03-03T16:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/"},"wordCount":408,"publisher":{"@id":"https:\/\/jjpbiologics.com\/#organization"},"keywords":["JJP1212"],"articleSection":["Zapytania"],"inLanguage":"pl-PL"},{"@type":"WebPage","@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/","url":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/","name":"Zapytanie z dnia 10\/02\/2023 - JJP Biologics","isPartOf":{"@id":"https:\/\/jjpbiologics.com\/#website"},"datePublished":"2023-02-10T14:16:22+00:00","dateModified":"2023-03-03T16:02:01+00:00","breadcrumb":{"@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/jjpbiologics.com\/zapytanie-z-dnia-10-02-2023-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jjpbiologics.com\/"},{"@type":"ListItem","position":2,"name":"Zapytanie z dnia 10\/02\/2023"}]},{"@type":"WebSite","@id":"https:\/\/jjpbiologics.com\/#website","url":"https:\/\/jjpbiologics.com\/","name":"JJP Biologics","description":"Innovative and revolutionary biologics","publisher":{"@id":"https:\/\/jjpbiologics.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jjpbiologics.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/jjpbiologics.com\/#organization","name":"JJP Biologics","url":"https:\/\/jjpbiologics.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/jjpbiologics.com\/#\/schema\/logo\/image\/","url":"https:\/\/jjpbiologics.com\/wp-content\/uploads\/2021\/06\/cropped-Artboard-31.png","contentUrl":"https:\/\/jjpbiologics.com\/wp-content\/uploads\/2021\/06\/cropped-Artboard-31.png","width":1000,"height":567,"caption":"JJP Biologics"},"image":{"@id":"https:\/\/jjpbiologics.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/jjpbiologics.com\/#\/schema\/person\/85e5b4f7346f1b3e0e153562849f7a43","name":"jjp","image":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/jjpbiologics.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7af8c453e36d80c5694e711800454903b7530678990eb7442d82d1b8c1f95609?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7af8c453e36d80c5694e711800454903b7530678990eb7442d82d1b8c1f95609?s=96&d=mm&r=g","caption":"jjp"},"url":"https:\/\/jjpbiologics.com\/pl\/author\/jjp\/"}]}},"featured_image_src":" ","featured_image_src_square":" ","author_info":{"display_name":"jjp","author_link":"https:\/\/jjpbiologics.com\/pl\/author\/jjp\/"},"category_info":"<a href=\"https:\/\/jjpbiologics.com\/pl\/category\/zapytania\/\" rel=\"category tag\">Zapytania<\/a>","tags_info":"<a href=\"https:\/\/jjpbiologics.com\/pl\/tag\/jjp1212\/\" rel=\"tag\">JJP1212<\/a>","social_share_info":"<a data-share=\"facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/\" class=\"pl-facebook-share social-share-default pl-social-share\" target=\"_blank\"><i class=\"fab fa-facebook-f\" aria-hidden=\"true\"><\/i><\/a><a data-share=\"twitter\" href=\"https:\/\/twitter.com\/share?url=https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/\" class=\"pl-twiiter-share social-share-default pl-social-share\" target=\"_blank\"><i class=\"fab fa-twitter\" aria-hidden=\"true\"><\/i><\/a><a data-share=\"linkedin\" href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/jjpbiologics.com\/pl\/zapytanie-z-dnia-10-02-2023-2\/\" class=\"pl-linkedin-share social-share-default pl-social-share\" target=\"_blank\"><i class=\"fab fa-linkedin-in\" aria-hidden=\"true\"><\/i><\/a>","wordExcerpt_info":"<p>RFP2302_T01_JJA_01 Legal services<\/p>\n<ul>\n<li>W zwi\u0105zku z realizacj\u0105 projektu rozwoju kandydata na lek o tytule \u201eDevelopment of first-in-class antibody therapy for treatment of the ultra-rare LABD indication as well as for pulmonary and autoimmune diseases with IgA mediated pathology, using Companion Diagnostics (CDx) patient stratification for treatment with the JJP-1212&#8243; w ramach konkursu Rozw\u00f3j medycyny celowanej lub personalizowanej na bazie terapii kom\u00f3rkowych lub produkt\u00f3w bia\u0142kowych, organizowanego przez Agencj\u0119 Bada\u0144 Medycznych, og\u0142aszamy zapytanie ofertowe na realizacj\u0119\u00a0<b style=\"font-size: 16px\">us\u0142ugi\u00a0<\/b><b>przegl\u0105du prawnego umowy z CRO dotycz\u0105cej przeprowadzenia badania klinicznego fazy 1 oraz udzia\u0142 w negocjacjach<\/b><b style=\"font-size: 16px\">\u00a0<\/b><b style=\"color: #121619;font-size: 16px\">(ang.\u00a0<\/b><b>legal review of the agreement with the CRO regarding conducting of Phase 1 clinical study and participation in negotiations<\/b><b style=\"color: #121619;font-size: 16px\">)<\/b>.<\/li>\n<li style=\"font-size: 16px\">Szczeg\u00f3\u0142y zapytania zostan\u0105 przekazane ka\u017cdorazowo po podpisaniu umowy o zachowaniu poufno\u015bci, w terminie 2 dni, lub po zg\u0142oszeniu si\u0119 podmiotu z\u00a0aktywn\u0105 umow\u0105 o zachowaniu poufno\u015bci. Wz\u00f3r umowy do pobrania\u00a0<a style=\"font-size: 16px;background-color: #ffffff\" href=\"http:\/\/jjpbiologics.com\/wp-content\/uploads\/2023\/03\/2023_01_20_bi-lingual-NDA-JJPBio.docx\">LINK<\/a>.<\/li>\n<li>Termin na sk\u0142adnie ofert: 24.02.2023.<\/li>\n<li style=\"font-size: 16px\">Pytania i kontakt w zwi\u0105zku z zapytaniem prosz\u0119 kierowa\u0107 na adres:\u00a0<img src=\"image\/png;base64,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\" alt=\"\" \/><img src=\"image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAABIAAAAYCAMAAADAi10DAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAHRUExURQAAAAAAAAAAAAAAAAAAKwAkJCQkJAAAICAgIAAAHAAaGhoaGhcXFxQUFBISEg4OHBgYGBYWFhUVFRQUHxQUFBMTExMTHBEaGhAZGQ8WHRYWFhMaGhMZGRIYGBAWFhAWGxAVGw8UGhQUGhMYGBMYGBIXGxIWGhAVGRUVGRAUGBAYGBIWGhQXGhMWGRIWGRIVGxIYGBIVGxQXGhEWGRQWGRMWGRMWGBMVGBMVGxIXGhIXGREWGREUGRMVGBMYGhMVFxIXGREWGBEVGhMXGhIWGhIWGhIWGBIWGhMVGREVGREXGRMVGRMVGREXGBEWGhIWGhIWGRIVGREXGBEWGRMWGRIXGRIWGRIVGhEVGREWGRMWGRIXGhIVGhIXGBIVGhIWGREWGRIXGRIWGRIWGBIWGRIWGhIWGRIWGhIWGBIWGBIXGRMXGREWGRIWGhIXGRIXGhIVGREWGBMWGhEWGRIWGRIXGRIWGRIWGRMXGRIXGRMXGhIWGRMWGhIWGBMWGhIWGRIWGREWGRMXGRIXGhEWGRIWGRIXGhIWGRIWGRIWGRMWGhMXGhIWGRIWGhIWGRIWGRIWGRIWGhIWGRIXGhMXGhMXGxMYGxMYHBQYGxQYHBQZHEBS4y4AAACSdFJOUwABAwUGBwcICAkKCgsNDhIVFxgZGhsbHh8jIygpKi8vMDIyNTY4Oj4+P0BFTlJTVFRWWltbXF5fYGNlZ2hrbG5wdXd4foCBgoSFhoaHiIuMjpGSl5eZmp6hoaKnqKiprK+1trzBwcLGx8jKzM3S1NXW29ze3t7f4ODi4uPk5ebn6Orq6+zt7fP09fX1+fr7\/P3+yrFjnQAAAAlwSFlzAAAXEQAAFxEByibzPwAAASlJREFUKFOljtVWgkEAhMdGxcJABTGwFQMDW7G7uxATuzuwxUZYfnf3aWWRJ9C5mDPfXMwZ\/FNRlYMzUwNFEV4EgtovKOecSXu1Pr9NwhKlD+b+4cUnJo17uvA15uiNFSlmlNBmEYbopwEheZnQFkY20ZdEQP1Oe1Bw6JKmV3kFNnkL0EGtoZoPum+2O0kJurgZWGaTmGC7SpQ5ST6q6RZ8D5gRG7wPkN2THFTRdcivJYN7oROIfia56OazwBFrwBzbUcrGKGlLOpaKgQVugs5Fbs7OTZLjjVn8gHr6mobGW3KSFTb\/RVZU7qeKU7qdDLkq2J1TtP7iPHTk29aaGhCorqkTGC+s\/JFSu\/XSxi2C9MKgGbkjLolcGQVkeCogLl1fmq3wwt8E\/ADExFOdjTthHwAAAABJRU5ErkJggg==\" alt=\"\" \/><img style=\"margin-bottom: 0px\" src=\"image\/png;base64,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\" alt=\"\" \/><\/li>\n<\/ul>\n<section data-id=\"a6c4773\" data-element_type=\"section\">\n<p style=\"font-family: Hind, sans-serif;font-size: 17px;font-style: normal;font-weight: 400;margin-bottom: 1.8em\">Otrzymane pytania dotycz\u0105ce specyfikacji zam\u00f3wienia:<\/p>\n<ol>\n<li style=\"list-style-type: none\">\n<ol>\n<li>W odniesieniu do \u017c\u0105danych referencji &#8211; jakiego rodzaju informacje spe\u0142ni\u0105 wymagania JJP Biologics? Czy mam rozumie\u0107, \u017ce powinienem uzyska\u0107 list (lub email) od zdecydowanego klienta potwierdzaj\u0105cy wykonanie okre\u015blonej pracy? Czy wiadomo\u015b\u0107 e-mail by\u0142aby wystarczaj\u0105ca? Czy wymagane by\u0142oby uzyskanie potwierdzenia na temat dok\u0142adnej liczby um\u00f3w, kt\u00f3re przegl\u0105dali\u015bmy? Obawiamy si\u0119, \u017ce klient mo\u017ce nie pami\u0119ta\u0107 dok\u0142adnie, lub uzyskanie dok\u0142adnych informacji mo\u017ce by\u0107 trudne, zw\u0142aszcza w przypadku instrukcji wykonanych jaki\u015b czas temu, lub je\u015bli klientowi zale\u017cy na poufno\u015bci.<br \/><b style=\"font-size: 17px\">Odpowied\u017a:<\/b>\u00a0Email od Cz\u0142onka Zarz\u0105du lub co najmniej osoby odpowiedzialnej za projekt na stronie klienta b\u0119dzie wystarczaj\u0105cy (email powinien zawiera\u0107 nazw\u0119 kancelarii zaanga\u017cowanej w projekt, typ umowy przygotowanej i negocjowanej przez kancelari\u0119 oraz dat\u0105 pracy nad umow\u0105).\n<p>\u00a0<\/p>\n<\/li>\n<li>Czy dobrze rozumiem, \u017ce limit powinien obejmowa\u0107 nie tylko przewidywane 60 h pracy, ale r\u00f3wnie\u017c wszelkie dodatkowe godziny pracy, w przypadku gdyby by\u0142y one potrzebne do zamkni\u0119cia projektu?<br \/><b style=\"font-family: inherit;font-size: 15px;font-style: inherit\">Odpowied\u017a<\/b>:\u00a0Prosimy o podanie stawki godzinowej, gdy\u017c jak opisujemy w RFP, chcemy by\u0107 rozliczani za prace prawne na podstawie ilo\u015bci przepracowanych godzin. Niemniej, chcemy ustali\u0107 limit na prac\u0119 nad pierwsz\u0105 wersj\u0105 umowy oraz w ramach dw\u00f3ch rund negocjacyjnych (kt\u00f3re oszacowali\u015bmy na max 60 godzin). Wszelkie dodatkowe negocjacje po drugiej rundzie mog\u0105 by\u0107 rozliczane powy\u017cej limitu.\u00a0<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<p style=\"font-size: 15px\">\u00a0<\/p>\n<\/section>\n<p>\u00a0<\/p>\n","comment_info":"No Comments","_links":{"self":[{"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/posts\/2400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/users\/990005"}],"replies":[{"embeddable":true,"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/comments?post=2400"}],"version-history":[{"count":0,"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/posts\/2400\/revisions"}],"wp:attachment":[{"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/media?parent=2400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/categories?post=2400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jjpbiologics.com\/pl\/wp-json\/wp\/v2\/tags?post=2400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}